Module 1: Introduction to biologics and biosimilars

Module 1: Introduction to biologics and biosimilars

Module 1: Introduction to biologics and biosimilars

A badge with ribbon in color black 1 point | An analog clock in color black 1 hour | A black calendar with white triangle in center that has a black exclamation point in the middle 05 Jan 2023 

Overview

About

Module 1 of Biosimilar Modules for Continued Professional Development comprises three short videos. In the first video, the talk given by presenter Gay Gauvin, Global Operations Director, Biosimilars, Amgen, will provide healthcare professionals with a basic understanding of biological drugs, what differentiates them from small-molecule drugs, as well as the fundamentals of biosimilars development and manufacturing. In the second video, Julien Taieb of Universite Paris Descartes, France and Dr Gunar Stemer of Vienna General Hospital, Austria will talk the viewers through the regulatory pathway for biosimilar approvals. The third video provides insights from Joao Gonçalves of Faculty of Pharmacy at University of Lisbon, Portugal, Dr Stemer, Simon Cheesman of University College London Hospitals, United Kingdom, Mr Taieb, and Dirk Arnold of Asklepios Tumorzentrun Hamburg, Germany regarding use of biosimilars in clinical practice.

Topics covered

  1. Introduction to biological drugs/biologics
  2. Defining biosimilars
  3. Biosimilars’ manufacturing
  4. Biosimilarity
  5. Steps to regulatory approval
  6. Extrapolation principlevii. Regulatory differences between biologics and biosimilars
  7. Complex structure of biological molecules
  8. Biosimilars’ pharmacovigilance
  9. Benefits of biosimilars

Learning outcomes

  1. Understanding of differences between biologics, biosimilars and small-molecule drugs
  2. Basic comprehension of the biologics’ and biosimilars’ manufacturing process
  3. Learning about biosimilarity
  4. Understanding the differences in regulatory pathways between biologics and biosimilars
  5. Learning about biologics’ and biosimilars’ complex structure and clinical implications
  6. Discovering biosimilars’ potential benefits

Sponsored by: